Please enter your details to request more information

Invest in the bio-pharmaceutical company, revolutionising one of the worlds quickest growing markets.

  • Discounted Share Offer – $0.50 per share
  • Standard Share Price - $1 per share
  • Forecast Share Price - $2.50 (yr 3)

151.5% growth forecast by 2029*

Plant-based neurotherapeutics are vital in the care of cancer, pain management and opioid replacement. We can supply these vitally needed, pharma-grade medicines at scale, to meet with staggering global demand.

  • Fully Licenced
  • Income Generating – An active cash generating operation
  • The global, regulated medicinal plant market is forecast to grow 23.5% until 2030 (CAGR)
  • The company EBITDA margin expands from 24% in 2026, to 42% in 2029, reflecting the benefits of vertical integration
  • Our wholly owned subsidiary own the IP, run the trials and hold clinical credibility

Our vertically controlled GMP-aligned platform is designed to produce standardised API’s and clinically governed therapeutics

We are running three concurrent clinical-research programmes:

  • Prostate cancer - SAMA award-winning research. Follow-on study under design.
  • Opioid replacement therapy - Plant-based opioid replacement therapy. 84% of patients stopped using opioids completely after 6 weeks
  • Lung cancer - Long-term complete remission of Stage IV metastatic NSCLC following combined short-course chemotherapy and plant-based supportive protocol.

*Based on Gross Profit. Download the investment Memorandum for full financial forecasts.

To be able to deal with your enquiry effectively we will need to contact you via telephone and/or email. By enquiring you consent to being contacted and you consent to your data being stored in accordance with European GDPR regulations. Privacy Policy

Disclaimer: Any person accessing this website or page and considering potential investment opportunities featured here, should make their own commercial assessment of an investment opportunity after seeking the advice of an appropriately authorised or regulated financial advisor. This website or page should not be construed as advice or a personal recommendation to any prospective investor. Investments of this nature carry risks to your capital and can go up or down. Past performance is not indicative of future results. Suitable appropriately qualified investors, sophisticated and high net worth investors only.